Loading…
Factors Predicting Prostate Specific Antigen Testing among First-Degree Relatives of Prostate Cancer Patients
First-degree relatives (FDRs) of prostate cancer patients are known to be at increased risk for the disease, yet relatively little is known about their screening behaviors. The current lack of consensus about the value of prostate cancer screening underscores the importance of examining why some men...
Saved in:
Published in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2004-05, Vol.13 (5), p.753-758 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | First-degree relatives (FDRs) of prostate cancer patients are known to be at increased risk for the disease, yet relatively
little is known about their screening behaviors. The current lack of consensus about the value of prostate cancer screening
underscores the importance of examining why some men at increased risk participate in screening and others do not. In this
study, variables from Protection Motivation Theory were used to identify predictors of prostate specific antigen (PSA) testing
in this at-risk population. Toward this end, scales assessing perceived vulnerability, perceived severity, response efficacy,
and self-efficacy for prostate cancer screening were administered to 82 unaffected male FDRs aged 40 and older. When recontacted
approximately 14 months later, 50% of FDRs were found to have undergone PSA testing in the interim. Older age, prior prostate
cancer screening, and a greater sense of personal efficacy about being able to undergo prostate cancer screening were found
to be significant ( P < 0.05) predictors of subsequently undergoing PSA testing. These findings provide partial support for the predictive validity
of Protection Motivation Theory variables and suggest the importance of considering efficacy beliefs in attempting to understand
decision-making about PSA testing in at-risk individuals. |
---|---|
ISSN: | 1055-9965 1538-7755 |
DOI: | 10.1158/1055-9965.753.13.5 |